RBM17 抗体 (AA 1-401)
Our Local Distributor
北京 101111
Quick Overview for RBM17 抗体 (AA 1-401) (ABIN7869320)
抗原
See all RBM17 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 1-401
-
原理
- RBM17 Antibody / RNA-binding motif protein 17 / Splicing factor 45
-
纯化方法
- Immunogen affinity purified
-
免疫原
- E.coli-derived human RBM17 recombinant protein (Position: M1-V401) was used as the immunogen for the RBM17 antibody.
-
亚型
- IgG
-
-
-
-
应用备注
- Optimal dilution of the RBM17 antibody should be determined by the researcher.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL
-
缓冲液
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- After reconstitution, the RBM17 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
-
-
- RBM17 (RNA Binding Motif Protein 17 (RBM17))
-
别名
- RBM17
-
背景
-
RBM17 antibody recognizes RNA-binding motif protein 17, also called Splicing factor 45, a splicing factor that participates in alternative mRNA splicing and exon definition. Encoded by the RBM17 gene on chromosome 10q24.32, this protein contains an RNA recognition motif (RRM) that binds pre-mRNA near splice junctions and interacts with other spliceosomal components including U2AF, SF3B, and SRSF proteins. RBM17 contributes to the assembly of the spliceosome and selection of 3' splice sites, influencing transcript diversity across cell types. Through its RNA-binding and protein-interaction domains, RBM17 regulates genes involved in cell cycle progression, DNA repair, and neuronal differentiation.
RBM17 is a core component of the exon junction complex and is involved in both constitutive and alternative splicing. It modulates inclusion of alternative exons in transcripts related to apoptosis, signaling, and cytoskeletal organization. Knockdown of RBM17 leads to widespread splicing defects and altered expression of cell-cycle genes such as cyclin D1 and BCL2. Elevated expression of RBM17 has been documented in cancers including glioma and breast carcinoma, where it contributes to enhanced proliferation and resistance to apoptosis. Because of this, RBM17 is emerging as a potential therapeutic target in oncology.
The RBM17 antibody is used in molecular biology and cancer research to detect expression and subcellular localization of this splicing regulator. Immunofluorescence studies reveal nuclear speckle localization consistent with active splicing sites, while western blotting identifies a ~55 kilodalton band. The antibody is effective in studies investigating RNA processing, transcriptome regulation, and splicing factor dynamics. Its use in chromatin immunoprecipitation combined with RNA sequencing (CLIP-seq) helps identify RBM17-binding targets genome-wide.
Functionally, RBM17 interacts with RNA helicases and spliceosomal scaffolds to ensure precise splicing during rapid transcriptional responses. In neurons, RBM17 supports maturation of transcripts necessary for synapse formation and plasticity. Dysregulation contributes to developmental disorders and neurodegeneration. The RBM17 antibody therefore provides a versatile tool for exploring RNA metabolism and gene expression regulation at both molecular and cellular levels. NSJ Bioreagents offers this antibody validated for high specificity in western blot, immunofluorescence, and immunohistochemistry, supporting studies in splicing control, neurobiology, and cancer progression. -
UniProt
- Q96I25
抗原
-